methyl 2-(4-chloro-3-fluorophenoxy)acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-chloro-3-fluorophenoxy)acetate
• 英文别名: Methyl 2-(4-chloro-3-fluorophenoxy)acetate
• 化学式: C₉H₈ClFO₃
• 分子量: 218.612
• InChiKey: NZTXQVBYOUZSHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-chloro-3-fluorophenoxy)acetate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以95%的产率得到2-(4-chloro-3-fluorophenoxy)acetic acid
  参考文献：
  名称：

  WO2020012339A5

  摘要：

  公开号：

  WO2020012339A5
• 作为产物：
  描述：

  4-氯-3-氟苯酚 、 溴乙酸甲酯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以98%的产率得到methyl 2-(4-chloro-3-fluorophenoxy)acetate
  参考文献：
  名称：

  WO2020012339A5

  摘要：

  公开号：

  WO2020012339A5

文献信息

• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3820843A1

  公开（公告）日：2021-05-19
• MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
  申请人：Denali Therapeutics Inc.

  公开号：US20210130308A1

  公开（公告）日：2021-05-06

  The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020012339A1

  公开（公告）日：2020-01-16

  The invention is directed to substituted carbon-linked bicycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (X): (X) wherein C', D', L2', L3', R1', R2', R3', R4', R5', R6', R7', R8', z1', z2', z3', z4', z5', z6', X1, and X2 are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• WO2020012339A5
  申请人：——

  公开号：WO2020012339A5

  公开（公告）日：2022-07-15